IP Verse

Switch Costimulatory Receptors - EP3549611

The patent EP3549611 was granted to The Trustees OF The University OF Pennsylvania on Jun 30, 2021. The application was originally filed on Jul 27, 2012 under application number EP19162250A. The patent is currently recorded with a legal status of "Revoked".

EP3549611

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Application Number
EP19162250A
Filing Date
Jul 27, 2012
Status
Revoked
Feb 16, 2024
Grant Date
Jun 30, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

OETKEMar 30, 2022WALLINGER RICKER SCHLOTTER TOSTMANN -

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5199942
DESCRIPTIONUS5350674
DESCRIPTIONUS5585362
DESCRIPTIONUS6120766
DESCRIPTIONUS6326193
DESCRIPTIONUS7285522
DESCRIPTIONWO0129058
DESCRIPTIONWO0196584
OPPOSITIONWO2013019615
SEARCHUS2010316646
SEARCHWO2005044996

Non-Patent Literature (NPL) Citations (60) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BECK et al., J Clin Oncol, (20060000), vol. 24, pages 2283 - 9
DESCRIPTION- BIERER et al., Curr. Opin. Immun., (19930000), vol. 5, pages 763 - 773
DESCRIPTION- BIRD et al., Science, (19880000), vol. 242, pages 423 - 426
DESCRIPTION- BLANSFIELD et al., J Immunother, (20050000), vol. 28, pages 593 - 8
DESCRIPTION- CHEEVER et al., Immunol Rev, (20080000), vol. 222, pages 357 - 68
DESCRIPTION- CHEMNITZ et al., J Immunol, (20060000), vol. 176, pages 6603 - 14
DESCRIPTION- DERRE et al., J Clin Invest, (20100000), vol. 120, pages 157 - 67
DESCRIPTION- DOUGAN et al., Annual Review of Immunology, (20090000), vol. 27, pages 83 - 117
DESCRIPTION- GARAUDE et al., Sci Transl Med, (20100000), vol. 2, no. 55, page 55ps2
DESCRIPTION- GHOSH et al., Glycobiology, (19910000), vol. 5, pages 505 - 10
DESCRIPTION- HENDERSON et al., Immun., (19910000), vol. 73, pages 316 - 321
DESCRIPTION- HOUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
DESCRIPTION- JUNE et al., Nat Rev Immunol, (20090000), vol. 9, page 704
DESCRIPTION- LAPORT et al., Blood, (20030000), vol. 102, page 20042013
DESCRIPTION- LEVINE et al., Proc Natl Acad Sci U S A, (20060000), vol. 103, pages 17372 - 17377
DESCRIPTION- LIU et al., Cell, (19910000), vol. 66, pages 807 - 815
DESCRIPTION- MARTIN-OROZCO et al., Immunity, (20090000), vol. 31, pages 787 - 98
DESCRIPTION- MUTTER, Trends Biochem. Sci., (19880000), vol. 13, pages 260 - 265
DESCRIPTION- PAULOS et al., J Clin Invest, (20100000), vol. 120, pages 76 - 80
DESCRIPTION- PAULOS et al., Science Translational Medicine, (20100000), vol. 2, pages 55 - 78
DESCRIPTION- RILEY et al., Blood, (20050000), vol. 105, pages 13 - 21
DESCRIPTION- ROSENBERG et al., New Eng. J. of Med., (19880000), vol. 319, page 1676
DESCRIPTION- SAMBROOK et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Press, (20010000), vol. 1 -3
DESCRIPTION- SAMBROOK et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Press, (20010000), vol. 1-3
DESCRIPTION- SCHROERS et al., Exp Hematol, (20040000), vol. 32, page 536
DESCRIPTION- UI-TEI et al., FEBS Letters, (20000000), vol. 479, pages 79 - 82
DESCRIPTION- WHERRY, Nat Immunol., (20110000), vol. 131, pages 492 - 9
DESCRIPTION- ZHAO et al., Cancer Res, (20100000), vol. 70, page 9062
OPPOSITION- Denise L Kellar, Ang S, Olivares S, Huls H And Cooper Ljn, "CD56-Specific Cells Can Distinguish between Allogeneic and Autologous CD56+ Targets", Molecular Therapy, The American Society of Gene & Cell Therapy, Beijing, Beijing , (20110501), vol. 19, no. S1, pages S192 - S193, XP055563574
OPPOSITION- Jeffrey C. Boyington, Aisha N. Riaz,* Apisit Patamawenu,* John E. Coligan,T Andrew G. Brooks,* And Peter D. Sun, "structure of cd 94 reveals a novel c-type lectin fold: implications foe the NK cell-associated cd94/nkg2 receptors ", immunity, (19990101), vol. 10, pages 75 - 82, XP055913705
OPPOSITION- Li Zhiguang, Chen Lin, Qin Zhihai, "Paradoxical Roles of IL-4 in Tumor Immunity The paradox of IL-4 in tumor immunity", Cellular & Molecular Immunology, (20091201), vol. 6, no. 6, page 415, XP055913639
OPPOSITION- Megan E. Prosser, Christine E. Brown,1 Michael C. Jensen, "Primary Human CD8+ T Cells Engineered To Express a PD1-CD28 Chimeric Receptor Are Co-Stimulated through the Exploitation of Tumor Expressed PD-L1", Molecular Therapy, (20110501), pages s192 - s193, XP055913652
OPPOSITION- Michel Sadelain, "T-cell engineering for cancer immunotherapy ", the cancer journal, (20091101), vol. 15, no. 6, pages 451 - 455, XP055913664
OPPOSITION- Powell D., Et Al., "Chapter 12", Powell D., Et Al., Medin Jeffrey, Et Al., Experimental and Applied Immunotherapy, Human Press, (20110000), pages 251 - 255,260-267, XP093003666
OPPOSITION- Prosser Megan Elizabeth, "Development of Genetic Engineering Platforms to Protect T Cells Against Functional Exhaustion", dissertation, (20110101), XP055913681
OPPOSITION- Prosser Megan E, Michael C. Jensen, John J. Rossi., "Mechanistic Studies of PD-1 Signaling in the Conversion of Effector T Cells to Functional Exhaustion", Molecular Therapy, (20090501), vol. 17, no. supp1, page s216, XP055913674
OPPOSITION- WILKIE, S. ET AL., "Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.", J. BIOL. CHEM., (20100101), vol. 285, pages 25538 - 25544, XP002762491
OPPOSITION- CARTER L L, ET AL., "PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20020101), vol. 32, doi:10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9, ISSN 0014-2980, pages 634 - 643, XP002980901
OPPOSITION- CHANG C., ET AL., "MOLECULAR CHARACTERIZATION OF HUMAN CD94: A TYPE II MEMBRANE GLYCOPROTEIN RELATED TO THE C-TYPE LECTIN SUPERFAMILY.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19950901), vol. 25., doi:10.1002/eji.1830250904, ISSN 0014-2980, pages 2433 - 2437., XP002046615
OPPOSITION- Chou Kuo-Chen, Elrod David W., "Prediction of membrane protein types and subcellular locations", Proteins: Structure, Function, and Bioinformatics, John Wiley & Sons, Inc., US, US , (19990101), vol. 34, no. 1, doi:10.1002/(SICI)1097-0134(19990101)34:1<137::AID-PROT11>3.0.CO;2-O, ISSN 0887-3585, pages 137 - 153, XP055913694
OPPOSITION- David Marc Davies, Maher John, "Adoptive T-cell Immunotherapy of Cancer Using Chimeric Antigen Receptor-Grafted T Cells", Archivum Immunologiae et Therapiae Experimentalis, Zak&lstrok;ad Narodowy im. Ossolińskich Wydawnictwo Polskiej Adademii Nauk, (20100601), vol. 58, no. 3, doi:10.1007/s00005-010-0074-1, ISSN 0004069X, pages 165 - 178, XP055048882
OPPOSITION- Berger, C. ; Turtle, C.J. ; Jensen, M.C. ; Riddell, S.R., "Adoptive transfer of virus-specific and tumor-specific T cell immunity", Current Opinion in Immunology, ELSEVIER, OXFORD., GB, GB , (20090401), vol. 21, no. 2, doi:10.1016/j.coi.2009.02.010, ISSN 0952-7915, pages 224 - 232, XP026058400
OPPOSITION- Megan E. Prosser; Christine E. Brown; Andrew F. Shami; Stephen J. Forman; Michael C. Jensen;, "Tumor PD-L1 co-stimulates primary human CD8cytotoxic T cells modified to express a PD1:CD28 chimeric receptor", MOLECULAR IMMUNOLOGY, PERGAMON, GB, GB , (20120315), vol. 51, no. 3, doi:10.1016/j.molimm.2012.03.023, ISSN 0161-5890, pages 263 - 272, XP028503025
OPPOSITION- M. C. Ngo, C. M. Rooney, J. M. Howard, H. E. Heslop, "Ex vivo gene transfer for improved adoptive immunotherapy of cancer", Human Molecular Genetics, Oxford University Press, GB, GB , (20110415), vol. 20, no. R1, doi:10.1093/hmg/ddr102, ISSN 0964-6906, pages R93 - R99, XP055400951
OPPOSITION- Bochner B. S., "Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors", Clinical & Experimental Allergy, Wiley InterScience, UK, UK , (20090301), vol. 39, no. 3, doi:10.1111/j.1365-2222.2008.03173.x, ISSN 0954-7894, pages 317 - 324, XP055913690
OPPOSITION- Olver S, Apte S, Baz A, Kienzle N, "The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?", TISSUE ANTIGENS., MUNKSGAARD, COPENHAGEN., DK, DK , (20070401), vol. 69, no. 4, doi:10.1111/j.1399-0039.2007.00831.x, ISSN 0001-2815, pages 293 - 298, XP055913643
OPPOSITION- Berry L. J., Moeller M., Darcy P. K., "Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells", TISSUE ANTIGENS., MUNKSGAARD, COPENHAGEN., DK, DK , (20091001), vol. 74, no. 4, doi:10.1111/j.1399-0039.2009.01336.x, ISSN 0001-2815, pages 277 - 289, XP055838046
OPPOSITION- Paulos C M; Carpenito C; Plesa G; Suhoski M M; Varela-Rohena A; Golovina T N; Carroll R G; Riley J L; June C H, "The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells", Sci Trans Med, (20100000), vol. 2, no. 55, pages 55 - 78, XP002750842
OPPOSITION- Xiaojun Liu, Raghuveer Ranganathan, Shuguang Jiang, Chongyun Fang, Jing Sun, Soyeon Kim, Kheng Newick, Albert Lo, Carl H. June, Yangbing Zhao, Edmund K. Moon, "A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors", Cancer research, American Association for Cancer Research, US, US , (20160315), vol. 76, no. 6, doi:10.1158/0008-5472.CAN-15-2524, ISSN 0008-5472, pages 1578 - 1590, XP055419334
OPPOSITION- Riley James L, June Carl H, "The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation", blood, (20050101), vol. 105, no. 1, doi:10.1182/blood-2004-, pages 13 - 21, XP055913702
OPPOSITION- Guedan S; Chen X; Madar A; Carpenito C; Mcgettigan S E; Frigault M J; Lee J; Posey A D; Scholler J; Scholler N; Bonneau R; June C H, "ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells", Blood, (20140000), vol. 124, pages 1070 - 1080, XP055145404
OPPOSITION- Carlos A Ramos, Gianpietro Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opinion on Biological Therapy, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 14712598, pages 855 - 873, XP055122639
OPPOSITION- Sun Lin, Gang Xiaokun, Li Zhuo, Zhao Xue, Zhou Tong, Zhang Siwen, Wang Guixia, "Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases", Frontiers in Immunology, (20210101), vol. 12, doi:10.3389/fimmu.2021.648182, XP055913709
SEARCH- BARRETT DAVID M ET AL, "Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells", 101ST ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; WASHINGTON, DC, USA; APRIL 17 -21, 2010, (201004), PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2521&sKey=0130c082-d2f1-4967-af2b-13063ee739e6&cKey=e7e9fefb-e8d7-4f0a-bf5c-cb407fb5e3ec&mKey=0591fa3b-afef-49d2-8e65-55f41ee8117e, (20150306), XP002736877 [X] 1-25 * the whole document * [Y] 1-25
SEARCH- MOON EDMUND K ET AL, "A PD1-CD28 "Switch Receptor" Is Able to Augment Mesothelin-Directed Chimeric Antigen Receptor T Cell Therapy in a Resistant In Vivo Model of Human Tumor", 17TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-GENE-AND-CELL-THERAPY (ASGCT); WASHINGTON, DC, USA; MAY 21 -24, 2014, (201405), URL: http://www.abstracts2view.com/asgct/view.php?nu=ASGCT14L1_520, (20150305), XP002736878 [T] * the whole document *
SEARCH- MEGAN E PROSSER ET AL, "Tumor PD-L1 co-stimulates primary human CD8cytotoxic T cells modified to express a PD1:CD28 chimeric receptor", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 51, no. 3, doi:10.1016/J.MOLIMM.2012.03.023, ISSN 0161-5890, (20120315), pages 263 - 272, (20120323), XP028503025 [XP] 1-25 * the whole document *
SEARCH- CARPENITO CARMINE ET AL, "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains", PNAS, NATIONAL ACADEMY OF SCIENCES, US, (20090303), vol. 106, no. 9, doi:10.1073/PNAS.0813101106, ISSN 0027-8424, pages 3360 - 3365, XP002605939 [Y] 21-25 * abstract *
SEARCH- Y. ZHAO ET AL, "Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor", CANCER RESEARCH, (20101115), vol. 70, no. 22, doi:10.1158/0008-5472.CAN-10-2880, ISSN 0008-5472, pages 9053 - 9061, XP055072178 [Y] 1-25 * see the whole document and in particular page 9054, col.2, para.2. *
SEARCH- CHRYSTAL M. PAULOS ET AL, "Putting the brakes on BTLA in T cell-mediated cancer immunotherapy", JOURNAL OF CLINICAL INVESTIGATION, (20100104), vol. 120, no. 1, doi:10.1172/JCI41811, ISSN 0021-9738, pages 76 - 80, XP055143199 [Y] 21-25 * page 76, column 2, paragraph 1 *
SEARCH- K. M. DENNEHY ET AL, "Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses", THE JOURNAL OF IMMUNOLOGY, (20060502), vol. 176, no. 10, doi:10.4049/jimmunol.176.10.5725, ISSN 0022-1767, pages 5725 - 5729, XP055147170 [X] 1-25 * see the whole document and in particular page 5725, col.1, para.1-2; page 5726, col.2, para.2; page5726, col.1, para.2. * [Y] 1-25

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents